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Acute myeloid leukemia (AML) is a heterogeneous
and fatal disease with an urgent need for improved
therapeutic regimens given that most patients die
from relapsed disease. Irrespective of mutation sta-
tus, the development of aggressive leukemias is
enabled by increasing dependence on signaling
networks. We demonstrate that a hyperactive signal-
osome drives addiction of AML cells to a tumor-
specific Hsp90 species (teHsp90). Through genetic,
environmental, and pharmacologic perturbations,
we demonstrate a direct and quantitative link be-
tween hyperactivated signaling pathways and
apoptotic sensitivity of AML to teHsp90 inhibition.
Specifically, we find that hyperactive JAK-STAT
and PI3K-AKT signaling networks are maintained
by teHsp90 and, in fact, gradual activation of these
networks drives tumors increasingly dependent on
teHsp90. Thus, although clinically aggressive AML
survives via signalosome activation, this addiction
creates a vulnerability that can be exploited with
Hsp90-directed therapy.INTRODUCTION
Acute myelogenous leukemia (AML) is a rare but lethal malig-
nancy (Siegel et al., 2012). Despite advances in targeted thera-
pies for AML, the standard induction chemotherapy regimen
has remained unchanged for the past three decades. Most adult
patients achieve initial remission, although 85% relapse within 2
to 3 years (Burnett et al., 2011). Thus, it is critical to understandCell Repthe molecular pathogenesis of AML to enable therapeutic
advances.
Since the introduction of all-trans retinoic acid (ATRA) for the
treatment of t(15;17) acute promyelocytic leukemia (APL) (Mi
et al., 2012) and imatinib for chronic myeloid leukemia (CML),
there has been an explosion of ‘‘targeted’’ compounds. The
ensuing agents designed to address unique genetic and molec-
ular lesions in AML (Perl and Carroll, 2007) have however gener-
ated disappointing results. Two main factors account for
these failures. First, AML can result from the cooperation of
several oncogenic events. Second, residual leukemia stem cells
(LSCs) provide the cellular reservoir for relapse (Guzman and Al-
lan, 2014). Available data suggest a reconfiguration of signaling
pathways including PI3K, MAPK, and STAT and a continued
requirement for an active ‘‘signalosome’’ to drive survival and
mitogenic signals.
We hypothesize that, due to the inherent participation of chap-
erone proteins in the folding and activation of a variety of kinases,
the oncogenic activation of the signalosome in leukemia may
be regulated by a specialized tumor-enriched Hsp90 species
(teHsp90). Whereas Hsp90 assists in the correct conformational
folding of a variety of proteins involved in physiological house-
keeping roles, specific modifications shunt Hsp90 to specialized
functions in stress (Moulick et al., 2011; Nayar et al., 2013; Ro¨hl
et al., 2013; Taldone et al., 2014). Tumor-specialized Hsp90 spe-
cies have been identified and referred to as ‘‘tumor-specific,’’
‘‘oncogenic Hsp90,’’ or ‘‘tumor-enriched Hsp90’’ (Moulick
et al., 2011; Nayar et al., 2013; Taldone et al., 2014); these spe-
cies are often found with enhanced association to oncogenic
proteins and can block their degradation (Bagatell andWhitesell,
2004; Moulick et al., 2011; Nayar et al., 2013; Ro¨hl et al., 2013;
Taldone et al., 2014). In diffuse large B cell lymphoma cells,
teHsp90 forms a complex with Bcl6 at its target gene promoters
and contributes to Bcl6-mediated gene silencing (Cerchietti
et al., 2009); in CML cells, teHsp90 sustains Bcr-Abl activityorts 13, 2159–2173, December 15, 2015 ª2015 The Authors 2159
Figure 1. PU-H71 Is Cytotoxic in a Subset of AML Cells while Leaving Normal Blood Cells Unharmed
(A) Growth of cells treated for 72 hr with PU-H71 (relative to untreated cells). PBL, peripheral blood lymphocytes.
(B) Cells were treated with or were not treated (control) with the Hsp90 inhibitor (Hsp90i), PU-H71. Percent annexin V+ cells relative to control after 48 hr treatment
with PU-H71 is shown.
(C) Immunoblots showing cleaved PARP after 24 hr treatment with PU-H71.
(legend continued on next page)
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and an active STAT5 signaling (Moulick et al., 2011); in virus-
associated lymphomas, teHsp90 regulates viral proteins, block-
ing latent and lytic viral functions (Nayar et al., 2013). Therefore,
whereas teHsp90 impacts numerous signaling pathways and
cellular functions, the signaling pathways impacted do not over-
lap across all tumor types, nor is regulation of the signalosome
behind its anti-apoptotic function in all tumor types. However,
all tumor types demonstrate a physically modified teHsp90
with higher affinity for ATP and its mimetics, thus providing a
basis for its specific pharmacologic targeting in the treatment
of diseases (Kamal et al., 2003; Taldone et al., 2014).
To investigate the potential relationship between an activated
signalosome in AML and teHsp90, here we use a combination of
genetic and pharmacologic approaches. We start by decipher-
ing the biological background of those AMLs more likely to
depend upon teHsp90 for their survival, at the blast as well as
the LSC level, using cells lines, primary specimens, and ex vivo
and in vivo models. We then link, in a step-by-step mechanistic
investigation, the vulnerability of the teHsp90-addicted AMLs to
an active signalosome. Our data demonstrated that, as adverse-
risk leukemias become dependent on greater numbers of
signaling networks, they increase recruitment of tumor-specific
chaperone functions and deepen their susceptibility to teHsp90
inhibitors.
RESULTS
Hsp90 Inhibition Induces Cell-type-Specific Cell Death
in Leukemia Cell Lines and Primary Samples
To gain insights into the biological characteristics of teHsp90-
dependent AML, we first investigated main drivers of sensitivity
to Hsp90 inhibition by evaluating the effect of Hsp90 inhibitors
in a spectrum of leukemia cell lines and primary samples with
different cytogenetic abnormalities and genetic backgrounds
(Tables S1 and S2). We used the small-molecule Hsp90 inhibitor
PU-H71, an agent with preferential binding to the teHsp90 spe-
cies. As PU-H71 has selective affinity for teHsp90, it can be used
as a sensor to measure the dependency of a tumor upon
teHsp90, in vitro and in vivo (Moulick et al., 2011; Nayar et al.,
2013; Taldone et al., 2014). PU-H71 has been shown to have a
potent anti-tumor activity in animal models for several types of
tumors by preferably targeting teHSP90 (Caldas-Lopes et al.,
2009; Marubayashi et al., 2010; Moulick et al., 2011; Nayar
et al., 2013) and is currently in phase I clinical trial for metastatic
solid tumors and lymphoma (http://www.clinicaltrials.gov,
NCT01393509 and NCT01581541).
We found that, for each leukemia cell line tested, PU-H71 in-
hibited growth in a dose- and cell-dependent manner. PU-H71
treatment also induced cell killing, with notable differences
observed among the cell lines (Figure 1A; cell killing represented
by y axis values below 0%). Importantly, we did not observe a
significant increase in sensitivity to PU-H71 in leukemia cell lines(D) Percent increase in caspase-3, 7 activity assay after 24 hr treatment with PU
(E) Immunoblots for Bcl-xL after 24 hr treatment with PU-H71.
(F and G) Percent annexin V+ cells relative to control for primary AML cells (F) or
(A, B, and D) Values denote mean ± SD (n = 4).
(F and G) Values denote SEM. See also Figure S1 and Tables S1 and S2.
Cell Repwhen grouped by mutations reported in the COSMIC database
(Figure S1A). We found that the most-sensitive cell lines were
MOLM-13, MV4-11, and M0-91 cells, in which over 95% of the
initial cell population was killed at 72 hr by concentrations as
low as 200 nM PU-H71. Other chemically distinct Hsp90 inhibi-
tors, such as 17-AAG, CNF-2024 (BIIB021), and PU-DZ13 ex-
hibited a similar activity spectrum (Figure S1B). Induction of
apoptosis as analyzed by annexin-V/7-AAD staining (Figures
1B and S1C) indicated a similar trend, with M0-91, MOLM-13,
and MV4-11 being most sensitive (LD50 < 500 nM); KG-1 and
Kasumi-1 displayed moderate sensitivity (LD50 ranged between
1 and 2 mM), and HEL cells were least sensitive (LD50 > 2 mM).
These observations were validated by PARP cleavage (Fig-
ure 1C) and activation of caspase 3,7 (Figures 1D and S1D). In
themost-sensitive cells, apoptosis was associated with downre-
gulation of anti-apoptotic molecules such as Bcl-xL (Figure 1E).
The apoptotic response of primary AML cells to PU-H71 treat-
ment was also variable (Figure 1F). Nearly 36% of the tested pri-
mary AML samples showed apoptosis of 50% or higher after
48 hr of treatment with 250 nM PU-H71. This fraction increased
to 60% at 500 nM PU-H71 (Figure 1F, bottom panel). When
compared to cytarabine (AraC), the cornerstone of induction
therapy and consolidation therapy for AML (Figure S1E), PU-
H71 was significantly more cytotoxic to primary AMLs.
Importantly, and potentially as an indication of its selective
binding to teHsp90 over the normal cell housekeeping Hsp90,
normal peripheral blood leukocytes (PBL) (Figure 1A) and mono-
nuclear cells from cord blood (CB) cells showed only minor
toxicity to PU-H71, even at the high concentration of 20 mM (Fig-
ure 1G). These data demonstrate that a subset of AMLs is highly
dependent on the activity of teHsp90 but that no specific karyo-
type or transforming event can be directly associated with the
sensitive subset (Figure 1A; Tables S1 and S2).
Inhibition of teHsp90 Depletes AML Oncoproteins, but
this Effect Does Not Correlate with Apoptotic Sensitivity
Hsp90 is required for the stabilization of oncogenic clients such
as BCR-ABL, NPM-ALK, and HER2 (Whitesell and Lindquist,
2005), and clinical translation of Hsp90 inhibitors to date has pri-
marily focused on tumors driven by these and other known
Hsp90 onco-clients (Moulick et al., 2011; Whitesell and Lind-
quist, 2005). Clinical activity observed for all Hsp90 inhibitors in
HER2-positive breast tumors and NSCLC with ALK transloca-
tions validates this as a successful strategy for a subset of tu-
mors (Jhaveri et al., 2014). The distinct apoptotic sensitivity of
AML cell lines toward PU-H71 could be due to effective disrup-
tion of Hsp90 interactions with its onco-clients in certain cell
lines, but not others. To test this hypothesis, we evaluated the ef-
fect of PU-H71 on two proteins demonstrated to be Hsp90
dependent in a majority of cancers, the RAF-1 and AKT kinases
(Trepel et al., 2010). The Hsp90 inhibitor dose dependently and
markedly reduced the steady-state levels of these proteins in-H71.
cord blood mononuclear cells (MNCs) (G) after 48 hr treatment with PU-H71.
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all the tested cells, irrespective of their apoptotic sensitivity to
Hsp90 inhibition (Figure 2A). In addition to these ‘‘pan-cancer’’
Hsp90 client proteins, PU-H71 also led to the degradation of leu-
kemia-specific oncoproteins, such asmutant FLT3 inMOLM-13,
TEL-TRKC in M0-91 (high Hsp90 sensitivity), AML1-ETO and
mutant cKIT in Kasumi-1 and SKNO-1 (intermediate Hsp90
sensitivity), and mutant JAK2 in HEL (low Hsp90 sensitivity)
and UKE-1 (high Hsp90 sensitivity; Figure 2A). These oncopro-
teins were previously reported to be degraded by Hsp90 inhibi-
tors in AML or other transformed cells (Floris et al., 2011; Yang
et al., 2007; Yao et al., 2003). In sum, PU-H71 depletes AML cells
of key oncogenic driver proteins, but this effect fails to translate
or be indicative of AML cells’ dependency status upon teHsp90.
AML Cells with High Apoptotic Sensitivity to teHsp90
Inhibition Display Activation of Key Signaling Pathways
Because we found that cell death upon PU-H71 treatment did
not correlate with degradation of specific oncogenic client pro-
teins characteristic of AML subtypes, we next proceeded to
investigate whether response to Hsp90 inhibitors was linked to
key AML-signaling networks such as the MAPK, PI3K-AKT-
mTOR, and JAK-STAT pathways (Echeverrı´a et al., 2011; Mou-
lick et al., 2011; Taipale et al., 2012). The rationale for the
pathway versus client approach is provided by recent global pro-
teomic analyses (Moulick et al., 2011; Nayar et al., 2013; Sharma
et al., 2012). These studies suggest that response to Hsp90 in-
hibitors may be dependent on tumor-driving teHsp90 clientele
networks and pathways as opposed to single oncogenic clients.
Indeed, in Hsp90-sensitive AML, we found constitutive acti-
vation of several signaling pathways, as indicated by the
presence of phosphorylated forms of NF-kB p65, STAT5, AKT,
and ERK1/2 (p44/42). These phosphoproteins were rapidly
decreased by PU-H71 treatment (Figure 2B for MV-411 and
MOLM13 cell lines and Figure 2C for a primary sample). The
decrease was readily detectable as early as 2 hr (Figure S2), at
a time the steady-state levels of the proteins were yet un-
changed. These observations were also corroborated using
flow cytometry assays. We found that PU-H71 treatment re-
sulted in a significant downregulation of p-AKT, p-NF-kB p65,
and p-STAT5 in both cell lines and primary samples (58.8%,
48.5%, and 62.0% in 1 mM PU-H71-treated MV4-11 cells and
65.2%, 65.3%, and 65.9%, respectively, in primary cells from
AML17; Figure 2D). Because of its specificity for teHsp90, PU-
H71 attached to a solid support can be used as a capture re-
agent to identify the teHsp90-interacting oncoproteins (Moulick
et al., 2011; Nayar et al., 2013; Taldone et al., 2014). We thus
performed PU-H71 pull-downs in AML cells with high sensitivity
to Hsp90 inhibition and demonstrated that, indeed, p-p65,
p-ERK, p-STAT5, and p-AKT are physically associated with
teHsp90 (Figure 2E). Together, the data suggest that teHsp90
binds to and maintains the activity of numerous signaling pro-
teins. AML cells may thus be dependent on preservation of these
signaling pathways in a teHsp90-dependent manner.
To investigate this hypothesis, we next evaluated all the AML
cells for their reliance on signaling pathways, specifically on
the MAPK, PI3K-AKT-mTOR, and JAK-STAT pathways, which
are known to play a role in AML survival (Perl and Carroll,
2007; Testa and Riccioni, 2007).2162 Cell Reports 13, 2159–2173, December 15, 2015 ª2015 The AuWe observed that cell lines most dependent for survival on the
activation of JAK-STAT, PI3K-AKT-mTOR, or MAPK pathways
were also those most likely to die when teHsp90 was inhibited
(Figures 3A–3C and S3A). Indeed, a significant correlation was
observed between the sensitivity of these cells to PU-H71
and their sensitivity to JAKi (slope 0.51 ± 0.19; R2 = 0.495;
p = 0.034), AKTi (slope 0.87 ± 0.21; R2 = 0.7034; p = 0.0047),
andMEKi (slope 0.73 ± 0.09; R2 = 0.9052; p < 0.0001; Figure 3D).
Similarly, phosphorylated forms of STAT5, ERK1/2, and AKT
were significantly increased in primary AML patient samples
with higher sensitivity to PU-H71 (2.97-, 2.82-, and 1.32-fold in-
crease and p = 0.0477, 0.0490, and 0.0395, respectively; Fig-
ure 3E, top panels), and consistently, PU-H71-sensitive primary
AML samples were also most sensitive to JAKi, MEKi, and AKTi
(Figure 3E, bottom panels). Phosphorylation alone was insuffi-
cient to indicate the addiction of AML to a signaling molecule
or its reliance on teHsp90; for example, whereas all Hsp90-
sensitive AMLs expressed constitutive levels of p-p38, a mole-
cule associated with leukemia proliferation (Birkenkamp et al.,
1999), these phosphorylated species were insensitive to
teHsp90 inhibition (Figures 2B, 2C, and S3B) and the viability
of these cells was unaffected by p38 inhibition (Figures S3C
and S3D).
Collectively, our findings suggest an intrinsic link between the
dependence of AML cells upon teHsp90-chaperoned signaling
networks involved in AML survival and their addiction to
teHsp90.
Addiction to teHsp90 Is a Result of Additive Dependence
on Activated Signaling Pathways
To quantify the contribution of each pathway toward teHsp90
addiction, we used cellular models in which the activation of
signaling pathways may be fine-tuned by several means. First,
we made use of FL5.12-derived isogenic cell lines. FL5.12 is
interleukin-3 (IL-3)-dependent for growth, proliferation, and sur-
vival. The level of p-STAT5, but not of p-AKT, is dependent on the
presence of IL-3, and constitutive activation of AKT can be found
in derivatives resistant to IL-3 withdrawal (Karnauskas et al.,
2003).
To investigate the effect of STAT5 activation on sensitivity to
teHsp90 inhibition, we cultured parental FL5.12 cells in 1 ng/ml
IL-3-containing media. As expected (Karnauskas et al., 2003),
STAT5 was active in these cells, as evidenced by increased
p-STAT5 levels (Figures 4A and 4B). Both the JAKi and PU-
H71, but not the AKTi, significantly decreased IL-3-stimulated
STAT5 activity (Figures 4A and 4B). When STAT5 activity was
increased by the addition of IL-3 to the culture media, cells
became more prone to die when treated with the JAKi or the
teHsp90 inhibitor (Figure 4C).
Next, we incorporated an additional layer of activation of the
signalosome by turning on AKT. To do so, we used FL5.12 cells
transfected with a constitutively activated, doxycycline (DOX)-
inducible myristylated form of AKT (mAKT) (Karnauskas et al.,
2003). Activation of AKT using mAKT was corroborated by the
increased phosphorylation of AKT observed by immunoblot (Fig-
ure 4D). Thus, in addition to STAT5 activation provided by the
IL-3 in the media, these cells have a constitutively activated
AKT. Increasing the activity of AKT by turning on mAKT led tothors
Figure 2. PU-H71 Treatment Depletes AML Cells of Major Leukemogenesis-Driving Proteins Irrespective of Their Apoptotic Sensitivity
(A–C) Immunoblot analysis for (A) AML (FLT3, TEL-TRKC, JAK2, c-KIT, and AML-ETO) and cancer (AKT and RAF-1) teHsp90 clients after 24 hr treatment with PU-
H71; (B and C) phosphorylated or total NF-kB p65, STAT5, AKT, ERK1/2, and p38 for leukemia cells treated for 6 hr with 1 mM PU-H71 are shown.
(D) Protein expression levels indicated as mean fluorescence intensity (MFI) for phosphorylated (upper panel) or total (lower panel) AKT, NF-kB p65, and STAT5.
Values denote mean ± SEM. ***p < 0.001.
(E) Pull-down assay for MV4-11 cells using PU-beads followed by immunoblotting for the indicated proteins. CB, control beads; PB, PU-H71-beads;WCL, whole
cell lysate.
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Figure 3. Dependence of AML Cells on Activated PI3K/AKT, JAK/STAT Pathways and teHsp90 Overlaps
(A–C) Percent cell death relative to untreated control evaluated at the indicated time points for a panel of leukemia cell lines treatedwith (A) 0.5 mMJAK1/2 inhibitor
(JAKi), (B) 5 mM AKT inhibitor (AKTi), or (C) 20 mM MEK1/2 inhibitor (MEKi).
(D) The apoptotic sensitivity of AML cells lines to PU-H71 (x axis) and to AKTi, JAKi, or MEK1/2i (y axis).
(E) (Top) Levels of pSTAT5, pERK, and pAKT evaluated by phosphoflow in primary AML samples with low or high PU-H71 apoptotic sensitivity. (Bottom) Percent
cell death after 48 hr treatment with JAKi, MEKi, or AKTi. Each symbol represents an individual sample. Values denote mean ± SEM. *p < 0.05 and **p < 0.01.
See also Figure S3.
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an increased reliance of these cells for survival on activated
AKT (Figure 4E, compare mAKT+AKTi to mAKT+DOX+AKTi;
p = 0.015) and, in turn, in a greater dependence on teHsp90 (Fig-
ure 4E, compare mAKT+PU to mAKT+DOX+PU; p = 0.035).
We thus conclude that the higher apoptotic effect observed for
PU-H71 versus AKTi or JAKi alone suggests a cooperation of
both the STAT andAKT pathways to the survival and proliferation
of these cells and indicate that their sensitivity to teHsp90 inhibi-
tionmay stem from combined, and potentially additive, addiction
to the AKT and the JAK/STAT pathways. Indeed, combination of
AKTi and JAKi resulted in significantly higher apoptosis in FL5.12
cells supplemented with IL-3 (Figure S4A).
To further test this observation, we employed an AML onco-
genic driver, FLT3-ITD. To this end, we utilized a leukemia
cell line with moderate sensitivity to PU-H71 (KG-1) and trans-
duced it with lentiviral vectors (pLVX-EF1a-IRES-mCherry) con-
taining either wild-type FLT3 (WT-FLT3) or FLT3 internal-tandem
duplication (ITD) (N51-FLT3) genes (Figure S4B). FLT3-ITD re-
sults in ligand-independent constitutive activation of FLT3, and
its downstream pathways include PI3K-AKT and JAK-STAT
(Brandts et al., 2005; Thiede et al., 2002). We found that the addi-
tional transformation event with FLT3-ITD mutation resulted in a
growth advantage over the parental cells (Figure 4F; N51-FLT3
[KG-1/N51], red squares; WT-FLT3 [KG-1/WT], green crossed
squares).
KG-1/N51 cells were more sensitive to teHsp90 inhibition
compared to the parental KG-1 or KG-1/WT cells (Figure 4G).
The percent annexin V+ cells after treatment of parental KG-1,
KG-1/WT, and KG-1/N51 with 1 mM PU-H71 for 48 hr were
34.7, 25.4, and 52.9, respectively. Higher sensitivity to teHsp90
correlated with increased activation of survival signaling net-
works, such as the JAK-STAT, PI3K-AKT, and MAPK pathways.
Immunoblots demonstrated that the phosphorylated form for
each of STAT5, AKT, ERK1/2, and NF-kB p65 was higher, with
their total protein levels remaining unchanged, in KG-1/N51 cells
(Figure 4H). By phospho-flow, we found 1.6-, 1.4-, 2.1-, 1.5-, and
2.6-fold increase in the phosphorylated ERK1/2, NF-kB p65,
STAT5, AKT, and S6 species, respectively, in KG-1/N51 cells
compared to KG-1/WT (Figure 4I). Phosphorylation of p38
MAPK was not changed in KG-1/N51 cells, demonstrating the
specificity of the transduction with FLT3-ITD in the activation
of JAK-STAT-, PI3K-AKT-, and ERK1/2-signaling pathways in
KG-1 cells.
Furthermore, to determine whether upregulation of JAK-
STAT-, PI3K-AKT-, and ERK1/2-signaling pathways by FLT3-
ITD results in increased dependence on teHsp90 chaperoning,
we performed pull-down assay using the solid-support immobi-
lized PU-H71 (PU-beads). We confirmed increased association
of teHsp90 with phosphorylated STAT5, AKT, ERK1/2, and
NF-kB p65 in KG-1/N51, but not in KG-1/WT cells, when
compared to parental KG-1 cells (Figure 4J), indicating that
these proteins are clients of teHsp90 and that the increased acti-
vation of these proteins resulting from the transduction with
FLT3-ITD require teHsp90. Immunoprecipitation assays were
also performed using an anti-FLT3 antibody to demonstrate an
increased association between FLT3-ITD and Hsp90 in KG-1/
N51, but not in KG-1/WT cells (Figure 4K). Importantly, in these
cells, we found that apoptosis induction by JAKi or AKTi signifi-Cell Repcantly correlated with cell death by the teHsp90 inhibitor (Fig-
ure 4L; JAKi R2 = 0.979, p = 0.090; AKTi R2 = 0.99, p = 0.048;
MEKi p = 0.161; p38i = 0.349).
In sum, these data indicate that additive upregulation of
signaling networks results in increased dependence upon
teHsp90, and thus, leukemic cells in this biologic state may
develop a higher vulnerability to teHsp90 inhibition.
Because FLT3-ITD is one transforming event capable of simul-
taneously activating these signaling pathways, we next tested
primary AML cells bearing FLT3-ITDmutations.We found indeed
that induction of apoptosis in FLT3-ITD+ primary AML cells by
500 nM PU-H71 treatment was significantly higher than in
FLT3-ITD primary AML cells (p = 0.02; Figure 4M). Importantly,
the total levels of Hsp90 were not significantly different in FLT3-
ITD+ or FLT3-ITD primary AML samples (p = 0.12; Figure 4N).
Of note, we still observed some differences in sensitivity to PU-
H71 (Figure 4M), for example, one FLT3-ITD-negative sample
with relative sensitivity to PU-H71 showing a 60% cell death
and one FLT3-ITD-positive sample with less sensitivity to PU-
H71 (40% cell death upon Hsp90 inhibition), suggesting that
FLT3-ITD alone would not be sufficient to predict for teHsp90-
addicted AML.
Taken together, our data strongly suggest that, in AML,
additive addiction conferred by the simultaneous activation of
PI3K-AKT- and JAK-STAT- and potentially ERK1/2-signaling
pathways results in an increased dependence on teHsp90 for
survival. The more the AML cell increases its signaling activity
through these pathways, the more the key components of these
pathways become associated with teHsp90. This increased
dependence on teHsp90 increases their vulnerability to Hsp90
inhibition.
Dependence of AML Signaling Networks on teHsp90 Is
Conserved at the Leukemic Progenitor and Stem Cell
Level
One of the challenges to AML therapy is the failure of current
chemotherapeutic drugs to eliminate LSCs (Felipe Rico et al.,
2013; Guzman and Allan, 2014). Thus, we also evaluated
whether the sensitivity of primary AML samples to PU-H71 will
extend to leukemia stem and progenitor cells. First, we evaluated
sensitivity of LSCs and lymphocyte populations defined by
immunophenotype from AML patient samples (Guzman and
Allan, 2014). We found that LSCs had higher sensitivity than
normal lymphocytes from the same patient sample to PU-H71
(p = 0.0005; Figure 5A). As observed in bulk AML blasts and
cell lines, LSCs also presented heterogeneity in their response
to PU-H71. In order to determine whether their sensitivity to
PU-H71 is also dependent on an active signalosome, we evalu-
ated the basal levels of p-STAT5 in LSCs, as it has been reported
that the JAK/STAT pathway plays a critical role inmalignant stem
cell growth (Cook et al., 2014). Indeed, we found that sensitive
LSC samples had significantly higher levels of basal phosphory-
lation of STAT5 (Figure 5B; R2 = 0.4900; p = 0.0242). Our findings
suggest an increased addiction of LSCs to teHsp90 in subsets
with constitutive STAT5 signaling, as we observed for leukemic
blasts.
To determine the effect of inhibition of teHsp90 in the function
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Figure 4. Activation of JAK, AKT, and ERK Pathways Renders AML Cells Addicted to teHsp90
(A and B) Immunoblot (A) and flow cytometry (B) of FL5.12 cells after 24 hr treatment with JAKi, AKTi, or PU-H71 (PU) in the presence or absence of IL-3.
(C) Percent dead cells in FL5.12 cells after 48 hr treatment with JAKi, AKTi, or PU.
(D and E) Immunoblots for pAKT (D) and percent apoptotic cells (E) of vector control- or mAKT-transfected cells treated with PU-H71, AKTi ± doxycycline (DOX)
for 24 hr or 48 hr, respectively.
(F) Percentage of mCherry+ cells KG-1/N51 or KG-1/WT over 30-day cultures.
(G) Percentage of apoptotic cells after 48 hr treatment with PU-H71.
(H and I) Phosphorylated protein levels in cells evaluated by immunoblot (H) or flow cytometry (I) (fold change of MFI for KG-1/N51 relative to KG-1/WT).
(J) Immunoblots of Hsp90-interacting proteins as isolated by PU-beads.
(legend continued on next page)
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Figure 5. Dependence of AML Signaling
Networks on teHsp90 Is Conserved at the
Leukemic Progenitor and Stem Cell Level
(A) Percent annexin-V-positive leukemia stem
cells (LSCs) and lymphocytes in primary AML
specimens treated with 500 nM PU-H71 for 48 hr.
Each color represents an individual sample.
(B) Correlation between p-STAT5 (y axis) and
sensitivity of LSCs to PU-H71 (x axis).
(C) Percent colony-forming units (CFUs) relative to
untreated control (UT) for primary AML cells or
CD34+ cord blood (CB) after 48 hr treatment with
500 nM PU-H71. Myeloid colonies are shown for
normal CB cells.
(D) Schematic representation for the ex vivo
engraftment assay to evaluate the effect of PU-
H71 treatment on the ability of LSCs to initiate
disease in immunodeficient mice.
(E and F) Percent engraftment of human AML cells
(E) and CD34+ CB cells from two units (CBa and
CBb) (F) after ex vivo treatment with PU-H71 for
24 hr. Each symbol represents an individual
mouse.
Values denote mean ± SEM.cells to form progeny after exposure to PU-H71 using colony-
forming assays. We found a significant decrease in colony for-
mation after exposure to 500 nM PU-H71 (75%98% reduction;
Figure 5C, circles). In contrast, PU-H71 demonstrated less
impairment of normal myeloid colony-forming ability of the
normal CD34+ progenitor cells obtained from umbilical CB cells
(Figure 5C, squares), demonstrating selectivity for malignant
progenitor cells.
To further determinewhether PU-H71 has an effect on the abil-
ity of LSCs to initiate disease, we performed xenotransplantation
assays after in vitro treatment with 500 nMPU-H71 (Figure 5D) of
primary AML samples with constitutive p-STAT5 and known
in vitro sensitivity for bulk tumor populations. We found that
PU-H71 in vitro treatment resulted in a significant decrease in
engraftment of human AML samples compared to untreated
controls (Figure 5E), demonstrating the ability of PU-H71 to
target LSCs. In contrast, the engraftment ability of normal
CD34+ CB cells was not significantly affected by PU-H71(K) Immunoblots for Hsp90 and FLT3 immunoprecipitated with an anti-FLT3 antibody.
(L) Correlation of the apoptotic sensitivity to PU-H71 (x axis) and to AKTi, JAKi, MEK1/2i, or p38i (y axis) in c
(M) Percent cell death for FLT3-ITD or FLT3-ITD+ primary AML cells after 48 hr exposure to PU-H71.
(N) Hsp90 expression of cells from (M) as measured by flow cytometry. Each symbol represents an individu
Values denote mean ± SEM. *p < 0.05; **p < 0.01;***p < 0.001. See also Figure S4.
Cell Reports 13, 2159–2173, Dein vitro treatment (Figure 5F), demon-
strating that normal HSCs have little, if
any, expression and/or dependence on
teHsp90.
Constitutive Activation of teHsp90-
Dependent Signaling Networks
Determines PU-H71 In Vivo Efficacy
Unlike experiments performed in culture
where cells can be under steady drugpressure and thus constant saturation of the target, tumor cells
in vivo are exposed to gradient drug levels, with high concentra-
tions soon after injection that decrease in a time-dependent
fashion as the drug is cleared from both the organism and the
tumor. Because pathways most dependent on teHsp90 are
also most sensitive to its pharmacologic inhibition, they remain
affected for the longest period of time upon single-dose admin-
istration of PU-H71. Thus, in vivo studies enable a kinetic anal-
ysis of individual teHsp90-dependent pathways and permit
correlation between individual signaling pathway suppression
and in vivo apoptosis induction. We performed such correlative
analyses in tumors generated from M0-91 cells (high apoptotic
sensitivity in vitro) and HEL cells (low apoptotic sensitivity
in vitro). In M0-91 tumors that harbor constitutively elevated
p-AKT and p-STAT5 levels, PU-H71 treatment resulted in a
marked induction of apoptosis, determined by an increase in
cleaved PARP (Figure 6A). Cleaved PARP in M0-91 was ob-
served up to 96 hr post-administration of one dose of PU-H71,ells treated for 48 hr.
al sample.
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Figure 6. PU-H71 Ablates In Vivo LSCs of Primary AML Samples with High pSTAT5 Levels
(A) Immunoblots (left) and graphed summary (right; means ± SEM) for the indicated proteins in M0-91 or HEL cells-engrafted mice after one dose of PU-H71
(75 mg/kg).
(B) Schematic representation for the in vivo treatment of MOLM-13-GFP-Luc xenografts.
(C) Whole-body luciferase imaging of MOLM-13-GFP-Luc xenografts before and during treatment with PU-H71.
(D) Top panel: representative plots for mouse (mCD45) and human (hCD45) BM cells harvested from MOLM-13-GFP-Luc xenografts after 2 weeks of treatment
with PU-H71. Bottom panel: percent human cells in xenografts treated with either PBS or PU-H71 (PU) is shown.
(E) Schematic representation for the in vivo AML-patient-derived xenograft (PDX) treatments.
(legend continued on next page)
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mirroring the parallel potent inhibition of both AKT and STAT
pathways (Figure 6A, left panel). The highest level of cleaved
PARP was observed in the interval of 12–72 hr post-PU-H71
administration, when both p-AKT and p-STAT5 levels were
reduced by 70%–100% (Figure 6A, left panel). It declined by
96 hr, when p-AKT, but not p-STAT5, recovered to baseline
levels (Figure 6A, middle panel).
Tumors derived from HEL cells (low apoptotic sensitivity; Fig-
ure 1B) were less sensitive than the M0-91 tumors to teHsp90
inhibition (Figure 6A). Nonetheless, and in contrast to tissue cul-
ture, when xenografted in nude mice, HEL cells demonstrated
low tomoderate expression level of p-AKT. This is not surprising,
as it has been reported that AKT activity can be stimulated in
AML cells by the environment. Consistent with our hypothesis,
elevation of AKT activity in xenografted HEL cells appears to
be necessary for tumor survival as PU-H71 induces markedly
higher apoptosis in xenografted HEL tumors (Figure 6A) than in
cultured HEL cells (Figure 1C). As with M0-91 tumors, highest
level of cleaved PARP was observed when both p-AKT and
p-STAT5 levels were reduced by PU-H71 by 70%–100% (in
the interval of 12–48 hr post-PU-H71 administration). PARP
cleavage diminished significantly when p-AKT recovered to
baseline levels (72 hr; Figure 6A, right and middle panels).
These data show that activation of key survival signaling mol-
ecules in AML in vivo remains modulated by the teHsp90. The
endogenous levels of these activated signalosome members,
the kinetics and potency of suppression of these pathways by
teHsp90 inhibition, and the gradual decline in PARP cleavage
that parallels the recovery of individual key signaling networks
further support our hypothesis that additive addiction of AML
to the teHsp90-regulated signaling networks is directly propor-
tional with the addiction of AML to teHsp90.
To further test whether the in vivo effectiveness of PU-H71 in
primary AML cell is dependent on the status of the teHsp90-
dependent signaling pathways, we used MOLM-13 cells as
they have both AKT and STAT pathways active. We transduced
these cells with CMV-GFP-T2A-luciferase lentiviral vectors to
express GFP and luciferase (MOLM-13-GFP-Luc). MOLM-13-
GFP-Luc cells were injected into NSG mice in order to visualize
tumor burden using the IVIS in vivo imaging system (Figure 6B).
The in vivo activation levels of p-STAT5 and p-S6 (as a surrogate
indicator of the AKT pathway activity) were evaluated in MOLM-
13-GFP-Luc cells using flow cytometry (Figure S5A). Animals
were evaluated for tumor burden prior the treatment with
75 mg/kg PU-H71 or saline three times a week for 2 weeks
when a high disease burden was confirmed by imaging (see Fig-
ure 6B). We found that PU-H71 treatment resulted in vivo abla-
tion of MOLM-13 cells reflected by the absence of luciferase
signal in the treated mice (Figure 6C). Eradication of leukemia
cells was confirmed by flow cytometry using GFP and human
CD45 (Figure 6D).
We extended our evaluation by establishing AML patient-
derived xenografts (PDX) (see Figure 6E for schematic represen-(F) Correlations between p-STAT5 (y axis; left panel) and pS6 (y axis; right panel
(G) Percent decrease in tumor burden after treatment with PU-H71 for seven PD
(H) Percent leukemia engraftment in secondary transplants for the indicated PDX
(I) CFUs of murine bone marrow cells evaluated from disease-free C57BL6 mice
Cell Reptation), in which primary AML samples were selected with
different levels of p-S6 and p-STAT5 (n = 7; Figure S5B). Once
the PDX models were established, we first re-evaluated the sta-
tus of p-S6 and p-STAT5 in the human AML cells obtained from
the PDX animals (Figure S5C; PDX-AML; n = 7). We classified
samples based on their levels of activation of PI3K/AKT and
JAK/STAT pathways, where we defined pS6 high level (>203),
pS6 mid-level (<53; >203), pS6 low level (<53), pSTAT5 high
level (>33), pSTAT5 mid-level (<33; >1.53), and pSTAT5 low
level (<1.53). We found that neither the activation levels of pS6
alone nor pSTAT5 alone were sufficient to correlate with
decrease in tumor burden after treatment with PU-H71 (Fig-
ure 6F). However, samples with high/mid levels of activation
for both pS6 and pSTAT5 had the greatest decrease in AML
tumor burden (Figure 6G), demonstrating that the highest level
of PU-H71 sensitivity occurred in PDX-AML samples, demon-
strating hyperactivation of both PI3K/AKT and JAK/STAT path-
ways. For example, PDX-AML4 with high activation of both
PI3K/AKT and JAK/STAT pathways demonstrated the largest
decrease in total tumor burden (90% decrease relative to vehicle
control; p = 0.004; Figures 6G and S5C). PDX-AML5 with mid-
activation for both PI3K/AKT pathway and JAK/STAT pathway
demonstrated an intermediate decrease in total tumor burden
(48% decrease relative to vehicle control; Figures 6G and
S5C), whereas PDX-AML9 that demonstrated mid-activation of
PI3K/AKT pathway but no STAT-pathway activity resulted in
only a 29.1% decrease in tumor burden (p = 0.0371) after
treatment with PU-H71 (Figures 6G and S5C). These data
strongly demonstrate that, with additive increased activation of
survival signaling networks, there is an increased dependence
on teHSP90.
Importantly, to determine the ability of PU-H71 to target LSCs
in vivo, we evaluated the ability of the human cells harvested
from the treated PDXs to initiate leukemia by performing second-
ary transplants (using equal numbers of human AML cells ob-
tained from the PU-H71-treated and vehicle control PDX mice).
We found a significant decrease in leukemia engraftment in
the secondary transplants derived from PDX-AML4 and PDX-
AML2 (96.3% and 68.4% [p = 0.02] decrease, respectively; Fig-
ures 6H and S5C), suggesting that PU-H71 effectively targets
LSCs in the samples with activation of both PI3K/AKT and
JAK/STAT pathways. Unfortunately, we were unable to evaluate
PDX-AML5 in the secondary transplant due to a lack of overall
engraftment. In contrast, the secondary transplants derived
from PDX-AML9 demonstrated a 1.7-fold increase in leukemia
cells after the animals were exposed to PU-H71, suggesting
that the treatment did not eliminate the LSCs from PDX-AML
samples with the activation of only one pathway (Figures 6H
and S5C). PDX-AML37, PDX-AML16, and AML-PDX33 were
not evaluated in secondary transplants. These data support
the concept that primary AML samples with constitutive activa-
tion of survival networks present higher dependence on
teHsp90. Importantly, the anti-AML effects of PU-H71 occurred) and decreased tumor burden after PU-H71 treatment (x axis).
X-AML xenograft cohorts grouped by their relative levels of pSTAT5 and pS6.
-AML xenograft cohorts grouped by their relative levels of pSTAT5 and pS6.
treated for 3 weeks with either PBS or PU-H71.
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with no toxicity to normal hematopoietic cells as demonstrated
by no changes in colony formation of bone marrow hematopoi-
etic stem and progenitor cells following chronic treatment with
PU-H71 (Figure 6I). This safety profile finding concords with
that seen on the phase 1 clinical study of PU-H71 in patients
with previously treated solid tumors, lymphoma, and myelopro-
liferative neoplasms (abstract by Gerecitano et al., 2015).
DISCUSSION
Despite the large number of targeted agents entering clinical
evaluation every year, only 5%–8% may reach registration.
There is an estimated 50% failure rate for oncology agents in
phase 3 studies. Such failures are especially expensive and
deprive many patients of potentially more-effective treatments,
highlighting the urgent need to implement means for patient se-
lection and trial enrichment. Our study aims to address this prob-
lem in AML. Targeted therapies designed to induce selective
apoptosis in leukemic cells are believed to be most promising
in leukemias, and we therefore focused our study on apoptotic
sensitivity (Testa and Riccioni, 2007).
To begin, we tested the teHsp90-specific inhibitor, PU-H71, in
a panel of genetically defined leukemia cell lines and primary
AML samples. Specifically, we evaluated a large panel of cell
lines and primary AML samples for sensitivity to Hsp90 inhibition
and correlated the response to somatic genetic aberrations,
expression of leukemia-associated proteins, and the specific
activated signaling pathways in different AML cells. We found
that teHsp90 inhibition resulted in a heterogeneous response
across leukemia cell lines and primary AML samples. This het-
erogeneity could not be attributed to the ability of PU-H71 to
inhibit several distinct and specific oncogenic targets in geneti-
cally diverse leukemia subsets as there was downregulation
and inhibition of numerous different leukemia driver proteins of
AML that were sensitive as well as resistant to PU-H71.
Interestingly, we found apoptotic sensitivity to teHsp90 inhibi-
tion to be a reflection of the cellular dependence for survival on
specific hyperactivated signaling pathways. Constitutive activa-
tion of multiple signaling networks in AML patients has been
shown to confer poor clinical outcomes (Kornblau et al., 2006).
These pathways include PI3K/AKT (Kornblau et al., 2006,
2011; Xu et al., 2003, 2005), JAK-STAT (Brady et al., 2012; Yosh-
imoto et al., 2009), and RAS/Raf/MEK/ERK (Kornblau et al.,
2006), all of which have been implicated in the pathogenesis of
the disease (Burnett et al., 2011; Cook et al., 2014; Tamburini
et al., 2007). Importantly, as the number of activated signaling
networks increased, patient survival was accumulatively
reduced (Kornblau et al., 2006), suggesting cooperativity among
pathways for transformation. Furthermore, activation of these
signaling networks is not always associated with FLT3 or JAK2
mutations (Brady et al., 2012; Kornblau et al., 2006). JAK/STAT
and PI3K/AKT pathways have been implicated in the survival
and self-renewal of malignant stem cells from CMLs and
AMLs, apart from their role in disease progression (Cook et al.,
2014; Xu et al., 2003, 2005). Together, these suggest that AML
treatment strategies should aim to simultaneously targetmultiple
signaling networks and provide an explanation to the improved
effectiveness of drugs that abrogate individual signaling net-2170 Cell Reports 13, 2159–2173, December 15, 2015 ª2015 The Auworks when combined with other agents. Our data indicate
that the engaging of these pathways in leukemia cells, whereas
advantageous to their aggressiveness, drives these cells to
become reliant on teHsp90. We hypothesized that, as more
than one pathway is activated, the dependence on teHsp90
also increases. Thus, the higher the activity of the JAK-STAT
and PI3K-AKT pathways, the greater the association of key
effectors of these pathways with teHsp90 and the larger the
sensitivity of AML to Hsp90 inhibition.
We manipulated, in isogenic leukemia cell lines, the activation
status of these pathways by exogenous or endogenous means.
Turning on STAT5 and/or AKT activity by exogenous IL3, acti-
vating oncogenic pathways by the introduction of a mAKT or
an ‘‘always on’’ receptor (FLT3 containing the ITD mutation), or
changing the microenvironment (HEL cells in tissue culture
versus xenograft) all resulted in the activation of JAK-STAT and
PI3K-AKT pathways; this in turn led to increased apoptotic
sensitivity to PU-H71. Among these three activators, the FLT3-
ITDmutation wasmore likely to be associated with the activation
of these signaling pathways; we also demonstrated higher sensi-
tivity of primary AML cells when compared to those harboring the
WT receptor. We found moderate sensitivity/resistance in AML
samples within FLT3-ITD-negative/positive groups, respec-
tively, consistent with reports for AML patients where activation
of multiple signaling networks was not always associated with
FLT3-ITD (Kornblau et al., 2006, 2009). These data support the
concept that teHsp90 dependence can be dictated by other ge-
netic and epigenetic events thatmodify the extent of activation of
JAK-STAT- and PI3K-AKT-signaling networks.
Further, we went on to probe our proposed mechanism by
pharmacologically modulating the activity of the JAK-STAT-
and PI3K-AKT-signaling pathways. We found that reducing the
activity of these pathways in native leukemia cells using small-
molecule inhibitors translated directly in cell killing; a close rela-
tionship existed between the ability of these pharmacologic
pathway suppressors and that of PU-H71 to induce apoptosis.
This relationship was also evident in xenotransplanted AML tu-
mors. Bymanipulating the kinetics of inhibition of these signaling
pathways by the teHsp90 inhibitor, we demonstrated that tumor
apoptosis was quantitatively and temporally linked to suppres-
sion of one or both of these pathways.
To demonstrate that such a role for teHsp90 is also observed
in vivo, we utilized a cell line with high levels of both JAK-STAT-
and PI3K-AKT-signaling pathways (MOLM-13) and found that
PU-H71 treatment effectively eliminated the tumor cells after
2 weeks of treatment. Furthermore, to evaluate the effect on
malignant stem and progenitor cells, we used established AML
patient-derived xenotransplants (PDX-AML). Here, we evaluated
samples with different levels of activation of JAK-STAT- and
PI3K-AKT-signaling networks as measured by phospho-flow
(i.e., levels of p-STAT5 and p-S6 in the transplanted human
AML cells). We found that samples with activation of both
p-STAT5 and p-S6 were sensitive to PU-H71 treatment in vivo
at the stem cell level, resulting in a decreased ability to initiate
disease in secondary transplants.
Important from a therapeutic perspective, concentrations of
PU-H71 that we report here to be toxic in the sensitive AML sub-
set are achievable in clinic at safe doses; in an ongoing phase 1thors
study, concentrationsofPU-H71of over 500nMwere recorded in
tumor cells at 24 hr after administration of dosesmuch lower than
themaximumtolerateddose (abstract byGerecitanoet al., 2013).
Many small molecules of variable selectivity and affinity for the
teHsp90 (Beebe et al., 2013; Moulick et al., 2011) have been de-
signed to inhibit Hsp90 in an ATP competitive manner, some of
which have been tested in clinical trials (Jhaveri et al., 2014),
including 17-DMAG and STA-9090 in leukemias. In AML, Hsp90
inhibitors have been evaluated in vitro and in phase I clinical trials
(Lancet et al., 2010; Reikvam et al., 2009). The phase I clinical trial
for the Hsp90 inhibitor KOS-1022 (17-DMAG) reported three
complete remissions out of 17 patients evaluated (Lancet et al.,
2010). This 18% response potentially indicates a subpopulation
of AML patients with high dependence on teHsp90 who may be
more likely to benefit from the incorporation of Hsp90 inhibitory
therapy in their treatment regimen. Our study proposes this pop-
ulation tobe characterized, in part, by a hyperactive signalosome.
The role of teHsp90 in maintaining dependence of tumors on
signaling networks is likely to be context dependent or unique
to each tumor type. Indeed, a recent study in multiple myeloma
cells found that IL-6-dependent activation of downstream
signaling networks in CD45+ cells resulted in increased sensi-
tivity to the Hsp90 inhibitor 17-DMAG (Lin et al., 2013).Thus,
the identification of the Hsp90-dependent proteomic signature
specific to each tumor type will be critical to the success of
teHsp90 inhibitory therapies in the clinic.
In summary, our work describes how hyperactivated signaling
networks drive a robust dependence on teHsp90 for survival of
AML cells. Our findings have significant clinical implications as
Hsp90 inhibitors can be evaluated clinically for AML therapy.
Our data demonstrate varied sensitivities to inhibition of teHsp90
in AML; we conclude that not all patients will benefit from an
Hsp90 drug. There is an urgent need to identify the responder
group in the patient population; our manuscript aims to present
the biological makeup of these patients. We demonstrated that
PU-H71 eliminates tumor burden as well as LSC in cell lines
and PDX models identified with ‘‘high’’ biomarker level (i.e.,
with a hyperactive signalosome). Our data also show that the
lower the AML is on our biomarker classification curve (i.e., lower
signalosome activity), the smaller the effect of PU-H71 (i.e., lower
cytotoxicity). Our manuscript suggests that teHsp90 inhibitory
therapy will likely benefit a subset of AML patients with constitu-
tive activation of PI3K-AKT/JAK-STAT-signaling pathways, and
thus clinical trials targeting teHsp90 should aim to enroll patients
with hyperactivation of these networks.EXPERIMENTAL PROCEDURES
Cell Lines and Primary Cells
Primary AML cells were obtained with informed consent and IRB approval
fromWeill Cornell Medical College-New York Presbyterian Hospital or Univer-
sity of Rochester. Cell lines were purchased from ATCC or DSMZ. FL5.12 cell
lines were cultured as described previously (Karnauskas et al., 2003). Addi-
tional details are provided in Supplemental Experimental Procedures.
Animal Studies
Experiments were carried out under an Institutional Animal Care andUseCom-
mittee (IACUC)-approved protocol, and institutional guidelines for the proper
and humane use of animals in research were followed.Cell RepXenografted Cell Lines
Four- to six-week-old nu/nu athymic female mice were obtained from Taconic
Farms. HEL and M0-91 were subcutaneously implanted in the right flank of
mice and allowed to reach 6–8 mm in diameter. Mice bearing tumors
were treated i.p. with 75 mg/kg of PU-H71. Tumors were homogenized and
proteins analyzed by western blot as previously described (Caldas-Lopes
et al., 2009).
Primary AML Xenotransplantation Assays
NOD/SCID or NSGmice were obtained from National Cancer Institute (NCI) or
Jackson Laboratories (JAX). Primary human cells (AML or CB; 2.5 3 106 cells
per mouse) were treated with 500 nM PU-H71 overnight and then injected i.v.
into sub-lethally irradiated with 2.7 Gy mice. Human engraftment was evalu-
ated 6–8 weeks after transplant as previously described (Hassane et al.,
2010). To evaluate the in vivo anti-leukemic activity of PU-H71, xenotrans-
plants were established by injecting 1 3 106 human primary AML cells into
sub-lethally irradiated NOD/SCID or NSG mice. Three weeks later, the mice
were treated with either PBS or 75 mg/kg PU-H71 three times a week for
3 weeks. To further investigate the LSC activity after treatments, equal
numbers of human AML cells were transplanted to secondary recipient
mice. The engraftment in the secondary mouse was evaluated 8–16 weeks
posttransplantation.
In Vivo Imaging
MOLM-13 cells were transduced with lentivirus carrying MSCV-GFP-
T2A-luciferase lentivector (System Biosciences). GFP+ cells were sorted
using FACSAria II cell sorter (BD Biosciences). NSG mice were transplanted
with 1 3 106 MOLM-13-GFP-Luc cells and were treated with 75 mg/kg PU-
H71 1 week postengraftment for a total of 2 weeks. The in vivo images were
captured before treatment (1 week) and 1 week after the treatment using the
IVIS imaging system (PerkinElmer) and were analyzed using the Living Image
software (Caliper Life Sciences).
Additional details are provided in Supplemental Experimental Procedures.
Cell Viability Assays
Cell viability assays were performed using annexin V/7-AAD, alamar blue,
or acridine orange/ethidium bromide staining as previously described (Cal-
das-Lopes et al., 2009; Hassane et al., 2010). Apoptosis was determined
by measuring caspase 3,7 activation or PARP cleavage. For primary AML
samples, cells were stained with CD34, CD38, and CD45 (BD Biosciences)
prior to annexin V/7-AAD staining. Levels of phosphorylated and total
proteins were determined by immunoblotting or by flow analysis, as
indicated. Colony-forming assays were performed as described (Guzman
et al., 2007).
Chemical precipitation/PU beads pull-down assays were performed as pre-
viously described (Moulick et al., 2011).
Additional details are provided in Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.10.073.
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